Clinical Trial Update: A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients [Phase 3]

View source ↗

Summary

A Phase 3 rollover study of BI 201335 in combination with pegylated interferon-alpha and ribavirin in treatment-experienced genotype 1 hepatitis C patients has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• BI 201335
• Pegylated interferon alpha (Pegylated interferon alfa)
• Ribavirin (ribavirin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Hepatitis C | Phase 3 | Status: COMPLETED | Results posted: 2015-07-31